Abstract
Background
Obinutuzumab, a Type II anti-CD20 antibody, is used to treat follicular lymphoma. A major mode of action of obinutuzumab is antibody-dependent cellular cytotoxicity (ADCC). Knowledge of the mechanisms of resistance to obinutuzumab is important for the development of next-line strategies to follow obinutuzumab-containing therapy, including obinutuzumab retreatment. Unfortunately, the mechanisms by which tumor cells acquire resistance to ADCC are still poorly understood. To address this, we examined the mechanisms of resistance to obinutuzumab-induced ADCC and the combination efficacy of obinutuzumab and clinically available agents in the established resistant cells.
Methods and results
We established cells resistant to obinutuzumab-induced ADCC using the non-Hodgkin lymphoma cell line RL and examined their mechanisms of resistance and the combination efficacy of obinutuzumab and clinically available agents. Comprehensive analysis by RNA sequencing of resistance mechanisms revealed that abnormal Fas signaling decreased sensitivity to ADCC in resistant clones. Combination treatment with prednisolone, a component of CHOP and CVP, was found to enhance ADCC sensitivity of RL cells and resistant clones and to significantly suppress tumor growth in xenograft models. Treatment with prednisolone upregulated expression of CD20 and an apoptosis-inducing protein BIM, which might augment perforin/granzyme B-mediated cell death. Furthermore, pretreatment of the effector cells with bendamustine enhanced ADCC activity, and treatment with obinutuzumab plus bendamustine showed significant antitumor efficacy in xenograft models. It was speculated that bendamustine upregulates ADCC activity by potentiating granules-mediated cell killing.
Conclusions
Our study revealed a novel mechanism underlying obinutuzumab-induced ADCC resistance and indicated that ADCC resistance could be overcome by combining obinutuzumab with prednisolone or bendamustine. This study provides a scientific rationale for obinutuzumab-retreatment in combination with clinically available chemotherapeutic agents for obinutuzumab resistant follicular lymphoma.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Follicular lymphoma (FL) is one of the most common types of indolent non-Hodgkin lymphoma, and its incidence is gradually increasing [1, 2]. Although outcomes for patients with FL have improved over recent decades with rituximab plus chemotherapy [3], most patients relapse and usually cannot be cured. Therefore, there are great unmet needs to develop novel therapeutic strategies and optimize existing therapies.
Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody [4]. In the randomized phase II GAUSS study, obinutuzumab induced a higher overall response rate compared to rituximab [5]. The randomized phase III GADOLIN [6] and GALLIUM [7] trials showed the efficacy of obinutuzumab plus chemotherapy. The GADOLIN trial compared obinutuzumab plus bendamustine with bendamustine alone in patients who did not respond to rituximab. The GALLIUM trial investigated the efficacy of obinutuzumab combined with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CVP (cyclophosphamide, vincristine, and prednisone), or bendamustine, compared with rituximab-based chemotherapy in previously untreated FL patients. Based on these results, obinutuzumab was approved for previously untreated or relapsed/refractory FL. In the clinical setting, retreatment of FL patients with rituximab has been reported to be effective for relapsed cases [8]. However, owing to the lengthy prognosis of FL and the insufficiently long clinical experience with obinutuzumab as compared to rituximab, there is still no evidence on the effectiveness of retreatment with obinutuzumab in patients who relapse after initial obinutuzumab treatment. This is an important issue to be resolved in the search for next-line therapies.
One of obinutuzumab’s major modes of action involves antibody-dependent cellular cytotoxicity (ADCC). ADCC is a killing process of target cells largely mediated by effector natural killer (NK) cells [9], and enhancement of ADCC is a critical approach in monoclonal antibody-mediated cancer therapy. Through defucosylation in its Fc portion, obinutuzumab has enhanced binding affinity to Fcγ receptor III, resulting in induction of ADCC greater than that of rituximab [4, 10]. The mechanisms involved in this process are including the degranulation of lytic granules, perforin and granzymes, and death receptor signaling such as the FasL–Fas cascade [11, 12]. Both granzymes and Fas signaling initiate apoptosis through multiple pathways [13]. It is important to understand the mechanisms of resistance to obinutuzumab in order to develop next-line strategies; however, relatively little is known about the mechanisms by which tumor cells acquire resistance to ADCC, and previous studies have uncovered only a few candidate genes associated with ADCC resistance (e.g., target antigens, XIAP, and target cell adhesion related genes) [14,15,16].
In this study, we established cells resistant to obinutuzumab-induced ADCC and investigated their mechanisms of ADCC resistance as well as the effectiveness of prednisolone, a component of CHOP/CVP, or bendamustine to overcome resistance. As a result, our current study provides novel insights into the molecular mechanisms underlying ADCC resistance and the efficacy of obinutuzumab-retreatment against obinutuzumab resistant FL.
Methods
Reagents
Obinutuzumab was provided by F. Hoffmann-La Roche Ltd. (Basel, Switzerland). Prednisolone for in vitro assay was purchased from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan). Prednisolone for in vivo assay was purchased from Shionogi & Co., Ltd. (Osaka, Japan). Bendamustine HCl was purchased from Selleck Chemicals (Houston, TX, USA).
Cell lines and cell culture
RL, SU-DHL-2, and SU-DHL-4 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), and were maintained in RPMI-1640 (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% FBS (Nichirei Biosciences Inc., Tokyo, Japan), 10 mM HEPES (Sigma-Aldrich), 0.45% d-glucose (Sigma-Aldrich), and 1 mM sodium pyruvate (Thermo Fisher Scientific, Waltham, MA, USA). CD16 (158V)/NK92 (NK92) cells were established as previously described [17]. NK92 cells were grown in MEMα (FUJIFILM Wako Pure Chemical Corporation) supplemented with 10% FBS, 10% horse serum (Thermo Fisher Scientific), 0.1 mM 2-mercaptoethanol (Thermo Fisher Scientific), 0.02 mM folic acid (Sigma-Aldrich), 0.2 mM myo-inositol (Sigma-Aldrich) and 0.02 μg/mL recombinant human IL-2 (PeproTech, Cranbury, NJ, USA). Farage, DB, HT, NU-DUL-1, SU-DHL-5, SU-DHL-8, and SU-DHL-10 cells were purchased from ATCC and maintained in RPMI-1640 ATCC modification (Thermo Fisher Scientific) with 10% FBS. STR-428 cells were obtained from the Japanese Collection of Research Bioresources Cell Bank (JCRB Cell Bank, Osaka, Japan) and maintained in RPMI-1640 ATCC modification with 10% FBS. The SU-DHL-6 cells from ATCC were obtained from F. Hoffmann-La Roche, under research agreement, and maintained in RPMI-1640 supplemented with 10% FBS, 10 mM HEPES, 0.45% d-glucose, and 1 mM sodium pyruvate. RC-K8 cells were obtained from JCRB Cell Bank and cultured in RPMI-1640 ATCC modification containing 20% FBS. All cells were cultured at 37 °C under 5% CO2.
Establishment of clones resistant to obinutuzumab-induced ADCC
RL cells were pretreated with 300 µg/mL of mutagen N-ethyl-N-nitrosourea (ENU; Sigma-Aldrich) to establish resistant clones more efficiently by inducing mutagenesis [18], and were then treated with effector NK92 cells at an effector/target (E/T) ratio 20:1 and 0.1 μg/mL of obinutuzumab for 24 h. CD20 positive cells were enriched by magnetic-activated cell sorting using anti-CD20 antibodies (BD Biosciences, San Jose, CA, USA). These ADCC induction and cell sorting procedures were repeated three times, and regrown cells were then single cell cloned.
ADCC assay
ADCC assay was performed using indicated target cells and NK92 cells as the effector cells. Target cells prelabeled with a cell-permeable fluorescent dye (calcein-AM; FUJIFILM Wako Pure Chemical Corporation) for 1 h were seeded into 96-well plates at 1 × 104 cells/well. For blocking assays, target cells were incubated for 30 min with 10 μg/mL antagonistic ZB4 anti-Fas monoclonal antibodies (GeneTex Inc., Irvine, CA, USA) or 10 μg/mL control IgG1 (Medical & Biological Laboratories Co., Ltd., Nagoya, Japan). Specific lysis was assessed at 4 h after exposure to NK92 cells at an E/T ratio 1:1 in the presence or absence of obinutuzumab. Fluorescence intensity of calcein was measured with a Varioskan LUX Multimode Microplate Reader (Thermo Fisher Scientific). %ADCC was calculated as follows: (experimental release − background)/(maximum lysis − background) × 100. Here, “background” means labeled target cells only and “maximum lysis” means labeled target cells lysed with 1% Triton X-100 (Sigma-Aldrich). The results of ADCC (%) are presented as mean ± SD. All experiments were performed at least twice, and representative results of one experiment are shown.
In vivo experiments
Female 5-week-old C.B-17/Icr-scid/scidJcl (SCID) mice were obtained from CLEA Japan, Inc. (Tokyo, Japan). Female 5-week-old CB17.Cg-PrkdcscidLyst bg-J /CrlCrlj (SCID Beige) mice were obtained from The Jackson Laboratory Japan (Kanagawa, Japan). Each mouse was inoculated subcutaneously with 5 × 106 tumor cells. Several weeks after tumor inoculation, mice were randomly allocated to control and treatment groups. To evaluate the antitumor activity of the test agents, tumor volume was measured twice a week. The antitumor activity was evaluated from tumor volume as described previously [19]. Human IgG or obinutuzumab was administered intravenously once a week for 3 weeks. Prednisolone or vehicle was administered orally daily from Day 1 to Day 5. Bendamustine or vehicle was intravenously administered on Day 1 and Day 2. Data points represent mean + SD. For assessment of the expression of CD20 in tumor samples, prednisolone or vehicle was administered orally daily from Day 1 to Day 4. All experiments were performed at least twice and the representative data of one experiment are shown.
Flow cytometry
For in vivo samples, tumors were harvested from SCID mice and digested using Tumor Dissociation Kit human (Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany). Cells were labeled with indicated antibodies or isotype control antibodies. Cells were analyzed by BD LSRFortessa X-20 (BD Biosciences) and FlowJo v10 software (Tree Star, Inc., Ashland, OR, USA). Anti-CD20, anti-CD19 antibodies, IgG2bκ isotype control, and IgG1κ isotype control were obtained from BD Biosciences. Anti-CD95 (Fas) antibodies were purchased from BioLegend (San Diego, CA, USA). All experiments were performed at least twice, and representative results are presented as MFI (mean fluorescence intensity).
Caspase-3/7 assay
Caspase-3/7 activity was measured using a Caspase-Glo 3/7 Assay Kit (Promega Corporation, Madison, WI, USA) in accordance with the manufacturer’s instructions. Caspase-3/7 assay was performed 4 h after treatment with or without agonistic CH-11 anti-Fas antibodies (Medical & Biological Laboratories) and the activity was measured with a Varioskan LUX Multimode Microplate Reader. The results are presented as mean ± SD. All experiments were performed at least twice, and representative results are presented.
RNA interference
siRNA pools were obtained from Horizon Discovery Group (Cambridge, UK). The following ON-TARGETplus siRNA pools were used: non-targeting control (siNC): D-001810-10-05 and siBCL2L11 (siBIM): L-004383-00-0005. siRNAs were transfected into cells by electroporation using NEPA21 TypeII (Nepa Gene Co., Ltd., Chiba, Japan).
CD107a assay
Target cells were incubated with effector NK92 cells at an E/T ratio 1:1 for 4 h in the presence of anti-CD107a antibodies or IgG1κ isotype control (BD Biosciences). For the last 3 h, cells were treated with BD Golgi Stop (BD Biosciences). After washing, cells were stained with anti-CD56 antibodies (BioLegend) or IgG1κ isotype control (BD Biosciences). Fluorescence was immediately measured with a BD LSRFortessa X-20. The results were analyzed with FlowJo software. The all experiments were performed at least twice, and the representative results are presented as mean ± SD.
RNA sequencing
Whole-transcriptome RNA sequencing was conducted by Takara Bio Inc. (Shiga, Japan) using a HiSeq 2500 sequencing system (Illumina, Inc., San Diego, CA, USA). Differential expression (RPKM: reads per kilobase of exon per million mapped reads) was evaluated by using the CLC Genomics Workbench (Qiagen, Hilden, Germany). Pathway analysis was performed with Ingenuity Pathway Analysis software (Qiagen).
Western blotting
Cells were lysed with cell lysis buffer (Cell Signaling Technology, Inc., Danvers, MA, USA) containing protease inhibitor cocktail (Sigma-Aldrich). Total cell lysates were subjected to SDS polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes by using an iBlot 2 Dry Blotting System (Thermo Fisher Scientific). Immunoblotting was carried out using the following antibodies; anti-caspase-3, anti-caspase-8, anti-cleaved caspase-8, anti-BIM, anti-Fas, and anti-β-actin antibodies (Cell Signaling Technology). Membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology), and imaging was performed with a ChemiDoc Touch imaging PC system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). All experiments were performed at least twice and the representative data of one experiment are shown.
Statistical analysis
All statistical analyses were performed in JMP software (SAS Institute Inc., Cary, NC, USA). Student’s t-test was used for paired samples. Dunnett’s test was used for multiple comparisons with the control group. Tukey’s HSD test was used for multiple comparisons within groups. For tumor growth experiments, P-values were adjusted for the Wilcoxon rank sum test by the Holm–Bonferroni method. P-values of less than 0.05 were regarded as statistically significant. Statistical tests used are described in the figure legends.
Results
Establishment and characterization of ADCC resistant RL clones
The non-Hodgkin lymphoma cell line RL carries the t(14; 18) chromosomal translocation [20], which is the hallmark of FL [21]. To investigate the efficacy of retreatment with obinutuzumab, we established cells resistant to obinutuzumab-induced ADCC by inducing ADCC with effector NK92 cells and obinutuzumab. To prevent the enrichment of only cells with low CD20 expression, CD20 positive cells were sorted by magnetic-activated cell sorting using anti-CD20 antibodies. The repopulated cells were single cell cloned, and each clone was named RL-OR-1, -2, -8, and -22 (Fig. 1a). In ADCC resistant clones, their sensitivity to ADCC was significantly downregulated compared to parental RL cells (Fig. 1b). To initially characterize the resistant clones, levels of CD20 antigen expression on the cell surface were quantified; flow cytometric analysis demonstrated that resistant clones showed varying levels of surface CD20 expression (Fig. 1c).
ADCC resistant clones show an abnormal Fas-mediated cell death
We next conducted RNA sequencing to better understand the molecular mechanisms of ADCC resistance, especially in clones with relatively high CD20 expression (RL-OR-8 and -22). Pathway analysis identified several gene sets that were significantly enriched in the resistant clones compared to parental RL cells (Supplementary Table 1). The full list of genes that were significantly enriched in resistant clones compared to parental RL cells is given in Supplementary Table S2. The second-most enriched, after the general category of “molecular mechanisms of cancer”, was “death receptor signaling”. NK cells have been shown to destroy target cells via exocytosis of proteolytic granules, i.e. perforin and granzymes, or engagement of the death receptor system, including the FasL–Fas cascade [11, 12].
We then examined the expression levels of death receptor Fas and observed that it is downregulated in all four resistant clones (Fig. 2a, and Supplementary Fig. S1a, b). To determine the responsiveness to Fas signaling, we examined the activation of caspase‐3/7 and caspase-8 after stimulation with monoclonal agonistic anti-Fas antibodies (CH-11). In parental RL cells, caspase-3/7 activation was observed in a CH-11-dose-dependent manner. In contrast, CH-11-induced caspase-3/7 activation was reduced in ADCC resistant clones (Fig. 2b and Supplementary Fig. S1c). The reduction of Fas-mediated caspase-8 activation was also observed in resistant clones (Fig. 2c), therefore it was shown that Fas signaling upstream of caspase-8 is deficient in these clones. Then, to explore the contribution of Fas signaling to NK92 cell-mediated ADCC, the effect of blockade with anti-Fas antibodies (ZB4) was assessed by ADCC assay (Fig. 2d). Blocking of Fas signaling significantly inhibited obinutuzumab-induced ADCC activation in parental cells, but had no effect in resistant clones, indicating that suppression of Fas signaling induces decreased sensitivity to ADCC in these four resistant clones.
Pretreatment of target cells with prednisolone augments ADCC activity
To explore the efficacy of obinutuzumab-retreatment, we investigated the efficacy of combinations of clinically available chemotherapeutic agents in FL. Target cells were pretreated with candidate agents and the combination efficacy was assessed by ADCC assay. Among the each single agent of CHOP, pretreatment of cells with prednisolone upregulated ADCC sensitivity in parental cells and ADCC resistant clones (Fig. 3a), suggesting the efficacy of combination therapy with prednisolone. In the xenograft model using RL-OR-1, which shows relatively low CD20 expression, treatment with obinutuzumab (30 mg/kg) in combination with prednisolone (4 mg/kg) significantly increased antitumor activity compared with each single agent on Day 18, the day when animals reached euthanasia criteria in the control and obinutuzumab monotherapy groups (Fig. 3b). The study was conducted up to Day 22 according to the clinical treatment cycle. Pretreatment with prednisolone upregulated the sensitivity to Fas signaling in RL but not in all ADCC resistant clones (Supplementary Fig. S2a), indicating that prednisolone does not directly overcome resistance to obinutuzumab-induced ADCC by activating Fas signaling.
In order to elucidate the mechanisms of this combination treatment, we examined expression of CD20 and BCL2-like 11 (BCL2L11/BIM, an apoptosis-inducing protein), because previous studies reported that they are upregulated upon prednisolone treatment [20, 21]. We found that prednisolone upregulates surface CD20 antigen expression in vitro (Fig. 3c). Prednisolone-induced CD20 upregulation was also observed in the RL-OR-1 xenograft model (Supplementary Fig. S2b). Moreover, the gene expression of BIM was also upregulated from 2 to 72 h after treatment with prednisolone (Fig. 3d, Supplementary Fig. S2c). Knockdown of BIM caused downregulation of ADCC sensitivity in prednisolone-treated parental cells and ADCC resistant clones (Supplementary Fig. S2d, e).
Collectively, our data suggested the possibility that prednisolone shows combination efficacy by upregulating CD20 or BIM expression, which leads to the activation of perforin/granzyme B-mediated cell death rather than Fas signaling.
Pretreatment of effector cells with bendamustine enhances ADCC activity
We also examined the efficacy of bendamustine, another potent combination agent. Pretreatment of effector cells with bendamustine resulted in enhanced ADCC in parental cells and ADCC resistant clones (Fig. 4a), suggesting that bendamustine could alter effector cell functions. Additionally, in the RL-OR-22 xenograft SCID mouse model, which shows relatively high CD20 expression, treatment with obinutuzumab (30 mg/kg) plus bendamustine (13.3 mg/kg) significantly suppressed tumor growth compared with each single agent on Day 18, the day when animals reached euthanasia criteria in the control and obinutuzumab monotherapy groups (Fig. 4b). The study was conducted up to Day 29 in accordance with the clinical treatment cycle. We also examined the combination efficacy in SCID Beige mice which lack NK-cell activity. Combination treatment with obinutuzumab (30 mg/kg) and bendamustine (13.3 mg/kg) did not significantly inhibit tumor growth compared to bendamustine alone on Day 21, the day when animals reached euthanasia criteria in the control group (Fig. 4c). These results indicate that NK cell function is necessary for these combination effects.
To investigate whether bendamustine potentiates NK cell function, CD107a/LAMP1 expression, a marker of NK cell degranulation and activation [22], on NK92 cells after exposure to target cells with obinutuzumab was assessed. Pretreatment with bendamustine increased the ratio of CD107a+ NK92 cells after exposing to both parental cells and resistant clones with obinutuzumab treatment (Fig. 4c).
Based on these findings, it is suggested that the combination of bendamustine plus obinutuzumab upregulates ADCC activity by enhancing granules-mediated killing of target cells.
Combination efficacy in another non-Hodgkin lymphoma cell line
Finally, to examine the applicability of these models, the expression level of Fas in lymphoma cell lines was evaluated (Supplementary Fig. 3). Both Farage and RL cells showed similar surface expression levels of Fas; therefore, we examined the role of Fas signaling and combination efficacy in Farage cells. We observed consistent results concerning the inhibition of ADCC by blocking of Fas signaling using blocking antibodies (ZB4) in Farage cells, and pretreatment with prednisolone overcame this ADCC inhibition (Fig. 5a). In addition, pretreatment of effector cells with bendamustine resulted in enhanced NK92 cell-induced ADCC in Fas-inhibited Farage cells (Fig. 5b). Together, these results suggest that Fas deficiency could cause obinutuzumab-induced ADCC resistance in several cell types and that combination with prednisolone or bendamustine could overcome these resistances (Fig. 5c, d).
Discussion
The current study presents a comprehensive analysis of mechanisms of resistance to obinutuzumab-induced ADCC, and to our knowledge, is the first to reveal that abnormalities in Fas signaling can cause ADCC resistance. Fas is a transmembrane death receptor involved in cell death signaling; FasL is predominantly expressed on NK cells and T cells. The activation of Fas leads to recruitment of the cytosolic adaptor molecule FADD and caspase-8 and initiates the apoptotic cascade. We showed here that the expression levels of Fas are reduced and Fas signaling upstream of caspase-8 is deficient in the ADCC resistant RL clones. Because Fas signaling is a common mechanism of action in ADCC, impairment of Fas signaling probably also causes resistance to other ADCC-inducing antibodies other than obinutuzumab. Thus, further investigation would likely identify candidate biomarkers able to predict sensitivity to a variety of ADCC-mediating monoclonal antibodies.
Intriguingly, all of the obinutuzumab-induced ADCC resistant RL clones established here showed Fas signaling deficiency. This implies the importance of Fas signaling in conducting ADCC. In addition, Fas is highly expressed on germinal center B cells, and downregulation of Fas on B cells has been shown to be a mechanism through which they evade immune surveillance during the development of B cell lymphoma [23]. Alterations of Fas or other mutations that impair the FasL–Fas apoptotic pathway have been reported to be prominent in B cell malignancies and associated with poor prognosis [24, 25]. These findings imply that Fas signaling abnormalities are also potential mechanisms underlying relapsed and refractory FL after treatment with obinutuzumab in clinical practice.
Our non-clinical study in the ADCC resistant clones validated the efficacy of readministration of obinutuzumab combined with prednisolone. Prednisolone, which is classified as a glucocorticoid, is commonly used to treat non-Hodgkin lymphoma. Glucocorticoid bound to glucocorticoid receptors translocates into the nucleus, and controls transcription of multiple target genes through glucocorticoid response elements (GREs) [26]. Here we found that the expression of BIM, a member of Bcl-2 family, is upregulated by prednisolone as previously reported [27]. Since it is known that human promoter of BIM gene does not contain a GRE, we hypothesize that a GRE-dependent upstream regulator indirectly controls BIM transcription. Several anticancer drugs has been shown to induce the killing of tumor cells by upregulating BIM expression [28, 29]. Our data showed that knockdown of BIM inhibits ADCC sensitivity in prednisolone-treated parental cells and ADCC resistant clones. Based on these results, it was speculated that prednisolone enhances ADCC sensitivity through upregulating proapoptotic BIM expression.
As has been previously reported with acute lymphoblastic leukemia samples [20], we found that prednisolone upregulates surface expression of CD20, the target antigen of obinutuzumab. It has been found that the expression levels of the target antigens correlate with sensitivity to cetuximab-induced ADCC [30]. Thus, although the direct effect of CD20 upregulation remains to be determined in our resistant cells, it could also contribute to enhancing ADCC sensitivity. Loss or reduction of CD20 expression is known to be one of the mechanisms of resistance to the anti-CD20 monoclonal antibodies [31]. Further studies therefore may show the usefulness of prednisolone for reducing the emergence of such resistance.
Obinutuzumab has various mechanisms of action other than ADCC, including antibody-dependent cellular phagocytosis and direct cell death. We previously demonstrated that co-treatment with obinutuzumab plus prednisolone shows combined effects by enhancing DNA fragmentation and G0/G1 arrest in direct cell death resistant models [32]. Although it is unclear that the effect of BIM or CD20 induction on obinutuzumab to induce direct cell death, combination treatment with obinutuzumab plus prednisolone is expected to address a variety of resistance mechanisms.
Our data also showed the effectiveness of obinutuzumab plus bendamustine, an alkylating agent that shows a unique cytotoxicity [33]. Bendamustine therapy causes prolonged lymphopenia [34], however, the effects of bendamustine on NK cell function at the point of administration remain to be elucidated. Our results showed that pretreatment of NK92 cells with bendamustine enhances degranulation of NK92 cells after exposure to target cells with obinutuzumab. Therefore, treatment with bendamustine may act advantageously with NK cell function under short-term conditions by enhancing perforin/granzyme B-mediated pathway.
Conclusions
We currently clarify the mechanisms of resistance to obinutuzumab-induced ADCC caused by abnormal Fas signaling and presents the possibility that obinutuzumab in combination with prednisolone or bendamustine could overcome this resistance. Although further investigations are needed to evaluate the clinical efficacy, this is the first report to show the possibility that obinutuzumab-retreatment would be effective against obinutuzumab resistant non-Hodgkin lymphoma.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Abbreviations
- ADCC:
-
Antibody-dependent cellular cytotoxicity
- FL:
-
Follicular lymphoma
- CHOP:
-
Cyclophosphamide, doxorubicin, vincristine, and prednisone
- CVP:
-
Cyclophosphamide, vincristine, and prednisone
- NK cells:
-
Natural killer cells
- ENU:
-
N-ethyl-N-nitrosourea
- E/T ratio:
-
Effector/target ratio
- MFI:
-
Mean fluorescence intensity
- GREs:
-
Glucocorticoid response elements
- OBI:
-
Obinutuzumab
- HuIgG:
-
Human IgG
- PSL:
-
Prednisolone
- Benda:
-
Bendamustine
References
Dada R (2019) Diagnosis and management of follicular lymphoma: a comprehensive review. Eur J Haematol 103(3):152–163. https://doi.org/10.1111/ejh.13271
Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, Lopez-Guillermo A et al (2019) Follicular lymphoma. Nat Rev Dis Primers 5(1):83. https://doi.org/10.1038/s41572-019-0132-x
Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z et al (2020) Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J 10(7):74. https://doi.org/10.1038/s41408-020-00340-z
Tobinai K, Klein C, Oya N, Fingerle-Rowson G (2017) A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther 34(2):324–356. https://doi.org/10.1007/s12325-016-0451-1
Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O et al (2015) Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol 33(30):3467–3474. https://doi.org/10.1200/JCO.2014.59.2139
Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K et al (2016) Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 17(8):1081–1093. https://doi.org/10.1016/s1470-2045(16)30097-3
Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C et al (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377(14):1331–1344. https://doi.org/10.1056/NEJMoa1614598
Johnston A, Bouafia-Sauvy F, Broussais-Guillaumot F, Michallet AS, Traulle C, Salles G et al (2010) Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. Leuk Lymphoma 51(3):399–405. https://doi.org/10.3109/10428190903503404
Zahavi D, AlDeghaither D, O’Connell A, Weiner LM (2018) Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy. Antib Ther 1(1):7–12. https://doi.org/10.1093/abt/tby002
Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S et al (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115(22):4393–4402. https://doi.org/10.1182/blood-2009-06-225979
Martinez-Lostao L, Anel A, Pardo J (2015) How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res 21(22):5047–5056. https://doi.org/10.1158/1078-0432.CCR-15-0685
Gras Navarro A, Bjorklund AT, Chekenya M (2015) Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol 6:202. https://doi.org/10.3389/fimmu.2015.00202
Boivin WA, Cooper DM, Hiebert PR, Granville DJ (2009) Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab Invest 89(11):1195–1220. https://doi.org/10.1038/labinvest.2009.91
Evans MK, Sauer SJ, Nath S, Robinson TJ, Morse MA, Devi GR (2016) X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. Cell Death Dis 7:e2073. https://doi.org/10.1038/cddis.2015.412
Yoshida R, Tazawa H, Hashimoto Y, Yano S, Onishi T, Sasaki T et al (2012) Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells. Cancer Immunol Immunother 61(11):1905–1916. https://doi.org/10.1007/s00262-012-1249-x
Aldeghaither DS, Zahavi DJ, Murray JC, Fertig EJ, Graham GT, Zhang YW et al (2019) A mechanism of resistance to antibody-targeted immune attack. Cancer Immunol Res 7(2):230–243. https://doi.org/10.1158/2326-6066.CIR-18-0266
Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M et al (2011) Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 17(15):5060–5070. https://doi.org/10.1158/1078-0432.CCR-10-2927
Brammeld JS, Petljak M, Martincorena I, Williams SP, Alonso LG, Dalmases A et al (2017) Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations. Genome Res 27(4):613–625. https://doi.org/10.1101/gr.213546.116
Masuda C, Yanagisawa M, Yorozu K, Kurasawa M, Furugaki K, Ishikura N et al (2017) Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model. Int J Oncol 51(2):425–434. https://doi.org/10.3892/ijo.2017.4036
Dworzak MN, Schumich A, Printz D, Potschger U, Husak Z, Attarbaschi A et al (2008) CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood 112(10):3982–3988. https://doi.org/10.1182/blood-2008-06-164129
Jiang N, Koh GS, Lim JY, Kham SK, Ariffin H, Chew FT et al (2011) BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia. Exp Hematol 39(3):321–329, e321-323. https://doi.org/10.1016/j.exphem.2010.11.009
Bryceson YT, Pende D, Maul-Pavicic A, Gilmour KC, Ufheil H, Vraetz T et al (2012) A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 119(12):2754–2763. https://doi.org/10.1182/blood-2011-08-374199
Afshar-Sterle S, Zotos D, Bernard NJ, Scherger AK, Rodling L, Alsop AE et al (2014) Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. Nat Med 20(3):283–290. https://doi.org/10.1038/nm.3442
Scandurra M, Mian M, Greiner TC, Rancoita PM, De Campos CP, Chan WC et al (2010) Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP-21. Br J Haematol 151(3):221–231. https://doi.org/10.1111/j.1365-2141.2010.08326.x
Harris J, Ibrahim H, Amen F, Karadimitris A, Naresh KN, Macdonald DH (2012) Cellular (FLICE) like inhibitory protein (cFLIP) expression in diffuse large B-cell lymphoma identifies a poor prognostic subset, but fails to predict the molecular subtype. Hematol Oncol 30(1):8–12. https://doi.org/10.1002/hon.996
Xavier AM, Anunciato AK, Rosenstock TR, Glezer I (2016) Gene expression control by glucocorticoid receptors during innate immune responses. Front Endocrinol (Lausanne) 7:31. https://doi.org/10.3389/fendo.2016.00031
Wang Z, Malone MH, He H, McColl KS, Distelhorst CW (2003) Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J Biol Chem 278(26):23861–23867. https://doi.org/10.1074/jbc.M301843200
Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC et al (2006) Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 103(40):14907–14912. https://doi.org/10.1073/pnas.0606176103
Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A (2007) Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 4(10):1681–1689. https://doi.org/10.1371/journal.pmed.0040316 (discussion 1690)
Seo Y, Ishii Y, Ochiai H, Fukuda K, Akimoto S, Hayashida T et al (2014) Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer. Oncol Rep 31(5):2115–2122. https://doi.org/10.3892/or.2014.3077
Seyfizadeh N, Seyfizadeh N, Hasenkamp J, Huerta-Yepez S (2016) A molecular perspective on rituximab: a monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Crit Rev Oncol Hematol 97:275–290. https://doi.org/10.1016/j.critrevonc.2015.09.001
Fujimura T, Yamashita-Kashima Y, Kawasaki N, Yoshiura S, Harada N, Yoshimura Y (2021) Obinutuzumab in combination with chemotherapy enhances direct cell death in CD20-positive obinutuzumab-resistant non-Hodgkin lymphoma cells. Mol Cancer Ther 20(6):1133–1141. https://doi.org/10.1158/1535-7163.MCT-20-0864
Leoni LM, Hartley JA (2011) Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Semin Hematol 48(Suppl 1):S12-23. https://doi.org/10.1053/j.seminhematol.2011.03.003
Saito H, Maruyama D, Maeshima AM, Makita S, Kitahara H, Miyamoto K et al (2015) Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood Cancer J 5:e362. https://doi.org/10.1038/bcj.2015.86
Acknowledgements
The authors thank Dr. Yoshiaki Isshiki, Dr. Kazushige Mori, and Dr. Kaori Fujimoto-Ouchi (Chugai Pharmaceutical Co., Ltd.) for their helpful support and advices.
Funding
This research was funded by Nippon Shinyaku Co., Ltd.
Author information
Authors and Affiliations
Contributions
NK conceived the idea, designed and performed the experiments, analyzed the data, and drafted the manuscript. YYK, OK, and YY established the study concept and supervised this study. YYK, TF, SY, NH, OK, and YY interpreted the results and conducted critical revision to the manuscript. All authors contributed to the final manuscript and approved it for submission.
Corresponding author
Ethics declarations
Conflict of interest
All authors are employees of Chugai Pharmaceutical Co., Ltd.
Ethical approval
All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee at Chugai Pharmaceutical Co., Ltd., which is an institute accredited by AAALAC international and conformed to the Guide for the Care and Use of Laboratory Animals published by Institute of Laboratory Animal Research.
Consent to participate
Not applicable.
Consent to publish
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Kawasaki, N., Yamashita-Kashima, Y., Fujimura, T. et al. Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies. Mol Biol Rep 49, 4421–4433 (2022). https://doi.org/10.1007/s11033-022-07280-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-022-07280-w